Dataset Information


Deletion of 11q in neuroblastomas drives sensitivity to PARP inhibition [SNP array]

ABSTRACT: SNP arrays were combined with next generation sequencing (NGS) to precisely define the deleted region in 17 primary 11q-loss neuroblastomas and identify allelic variants in genes relevant for neuroblastoma aetiology. We assessed PARP inhibitor olaparib in combination with other chemotherapy medications using both in vitro and in vivo models. Overall design: CytoScan HD arrays (Affymetrix) were performed according to the manufacturer's directions on DNA extracted from 17 neuroblastoma tumor samples and 7 neuroblastoma cell lines.

INSTRUMENT(S): [CytoScanHD_Array] Affymetrix CytoScan HD Array

SUBMITTER: Jaime Font de Mora  

PROVIDER: GSE101533 | GEO | 2017-07-18



altmetric image


Deletion of 11q in Neuroblastomas Drives Sensitivity to PARP Inhibition.

Sanmartín Elena E   Muñoz Lisandra L   Piqueras Marta M   Sirerol J Antoni JA   Berlanga Pablo P   Cañete Adela A   Castel Victoria V   Font de Mora Jaime J  

Clinical cancer research : an official journal of the American Association for Cancer Research 20170822 22

Purpose: Despite advances in multimodal therapy, neuroblastomas with hemizygous deletion in chromosome 11q (20%-30%) undergo consecutive recurrences with poor outcome. We hypothesized that patients with 11q-loss may share a druggable molecular target(s) that can be exploited for a precision medicine strategy to improve treatment outcome.Experimental Design: SNP arrays were combined with next-generation sequencing (NGS) to precisely define the deleted region in 17 primary 11q-loss neuroblastomas  ...[more]

Similar Datasets

| GSE101989 | GEO
| PRJNA396155 | ENA
| GSE101990 | GEO
2008-10-26 | E-GEOD-13136 | ArrayExpress
| GSE13136 | GEO
2014-09-01 | E-GEOD-51297 | ArrayExpress
2008-10-09 | GSE13137 | GEO
2009-02-20 | GSE14880 | GEO
2008-10-26 | E-GEOD-13137 | ArrayExpress
2015-07-15 | E-GEOD-69869 | ArrayExpress